Many irreversible antagonists have been shown to inactivate G protein-coupled receptors (GPCRs) and used to study agonists and spare receptors. Presumably, they bind to primary (agonist) binding sites on the GPCR, although noncompetitive mechanisms of antagonism have been demonstrated but not thoroughly investigated. We studied noncompetitive antagonism by phenoxybenzamine and benextramine at ␣ 2A -adrenoceptors in stably transfected Chinese hamster ovary cells, benextramine and 4-diphenylacetoxy-N-[2-chloroethyl]piperidine hydrochloride (4-DAMP mustard) at endogenous muscarinic acetylcholine (mACh) receptors in human neuroblastoma SH-SY5Y cells, and benextramine at serotonin 5-HT 2A 
tor complexes (Herepath and Broadley, 1990; Adham et al., 1993; Agneter et al., 1993; Zhu, 1993; Tian et al., 1996; Kenakin, 1997; Morey et al., 1998; Koek et al., 2000) . Irreversible antagonists have also been used to label and count receptor subtypes, to investigate drug and receptor specificity and receptor structure (Jenkinson, 2003) , to investigate receptor trafficking (Taouis et al., 1987; McKernan et al., 1988) , and to unravel drug action mechanisms (Timmermans et al., 1985) . Selective inactivation of "unwanted" pharmacological receptor subtypes, although protecting the receptors of interest with a highly selective reversible competitive antagonist, has also been implemented to study and characterize receptors (Hieble et al., 1985; Eglen et al., 1994) .
Phenoxybenzamine is known to irreversibly bind to ␣-adrenergic, H 1 -histamine, and muscarinic acetylcholine (mACh) receptors (Timmermans et al., 1985; Eglen et al., 1994; Amobi and Smith, 1995; Giardinà et al., 1995 Giardinà et al., , 2002 Van der Graaf and Danhof, 1997; Ruffolo and Hieble, 1999; Van der Graaf and Stam, 1999; Frang et al., 2001 ). Benextramine has been known to irreversibly bind to ␣ 2 -adrenoceptors (Melchiorre, 1981; Belleau et al., 1982b; Lew and Angus, 1984; Hieble et al., 1985; Timmermans et al., 1985; Taouis et al., 1987; McKernan et al., 1988; Brink et al., 2000; Umland et al., 2001) , 5-HT 1A -serotonergic receptors (Stanton and Beer, 1997) , H 2 -histaminergic receptors (Belleau et al., 1982a) , and neuropeptide Y receptors (Melchiorre et al., 1994) . Present knowledge regarding the mechanism of action of benextramine is limited to the observations from predominantly radioligand binding studies, and it is generally assumed that benextramine irreversibly inactivates the ligand (primary or syntopic) binding sites at these receptors. 4-Diphenylacetoxy-N-(2-chloroethyl)piperidine (4-DAMP mustard) is known to bind to mACh receptors (Thomas et al., 1992; Eglen et al., 1994; Ehlert and Griffin, 1998; Sawyer and Ehlert, 1999; Ragheb et al., 2001; Umland et al., 2001) with moderate selectivity for M 3 -mACh receptors. It does not, however, discriminate between M 1 , M 2 , or M 4 -mACh receptors (Eglen et al., 1994) .
The elimination of pharmacological receptors by an irreversible competitive antagonist depends on both the concentration used and the incubation time (Furchgott, 1966; Kenakin, 1997) . Phenoxybenzamine has been typically used in vitro at concentrations of up to 10 M for 30 min (Piascik et al., 1988) , benextramine at concentrations of up to 100 M for 120 min (Van der Graaf et al., 1996) , and 4-DAMP mustard at concentrations of up to 40 nM for 4 h (Sawyer and Ehlert, 1999) .
Reports in literature suggest that some irreversible competitive antagonists may also display irreversible allosteric interactions (noncompetitive antagonism) (Van der Graaf et al., 1996; Brink et al., 2000) by altering agonist binding affinity, modifying agonist-receptor binding kinetics (Van Ginneken, 1977) , or even influencing signal transduction mechanisms. However, this has been difficult to prove (Jenkinson, 2003) . The irreversible antagonism of benextramine at prostanoid TP receptors cannot be prevented by the selective prostanoid TP-receptor antagonist SQ 30,741 (Van der Graaf et al., 1996) , suggesting that benextramine and SQ 30,741 bind to different binding sites (i.e., benextramine exhibits allotopic interactions at prostanoid TP receptors). The underlying mechanism, however, remains elusive.
In the present study, we examined three classical irreversible competitive antagonists, namely, benextramine at ␣ 2A -adrenoceptors and 5-HT 2A receptors, phenoxybenzamine at ␣ 2A -adrenoceptors, and 4-DAMP mustard at mACh receptors. For any observed noncompetitive interactions, the mechanisms were investigated, including possible allosteric interactions, where agonist affinity at the syntopic binding site of the GPCR is altered or signal transduction is modulated downstream. We have been able to show that benextramine displays irreversible noncompetitive antagonism by binding at a site affecting the ␣ 2A -adrenoceptor-G i protein coupling or G protein function, without affecting the GTP binding capacity of the G i -related G␣ o protein. In addition, we have been able to show that benextramine also irreversibly and noncompetitively inhibits the signaling of ␣ 2A -adrenoceptors through G s proteins, as well as the signaling of mACh receptors and serotonin 5-HT 2A receptors through G q proteins.
Materials and Methods
Cell Lines. In this study, cultured cell lines expressing ␣-adrenoceptors and mACh receptors, respectively, were used. Two Chinese hamster ovary (CHO-K1) cell lines, stably transfected to express the wild-type porcine ␣ 2A -adrenoceptor at high numbers (cell line denoted ␣ 2A -H) and low numbers (cell line denoted ␣ 2A -L) respectively, were kindly provided by Dr. Richard Neubig (Department of Pharmacology, University of Michigan, Ann Arbor, MI). The pharmacological profiles and receptor expression characteristics of the ␣ 2A -H and ␣ 2A -L cell lines have been previously characterized. The determined ␣ 2A -adrenoceptor concentrations were reported as 19 Ϯ 2 pmol/mg membrane protein for ␣ 2A -H and as about 1 pmol/mg membrane protein for ␣ 2A -L (Brink et al., 2000) . We confirmed the high receptor expression for ␣ 2A -H in our laboratory, determined as 46 Ϯ 5 pmol/mg membrane protein. These cell lines were used to investigate the mechanisms of antagonism of the irreversible ␣-adrenoceptor-blocking drugs phenoxybenzamine and benextramine.
We also used human neuroblastoma cells (SH-SY5Y; American Type Culture Collection, Manassas, VA), that endogenously express predominantly M 3 -mACh receptors (Slowiejko et al., 1996) , with some evidence for M 1 and M 2 -mACh receptors (Kukkonen et al., 1992) . The K D value of [
3 H]N-methyl scopolamine binding at the endogenous mACh receptors in intact cells was previously reported as 0.2 nM and the B max as 100 to 150 fmol/mg membrane protein (Lambert et al., 1989) . This cell line was used to investigate the mechanisms of antagonism of the irreversible mACh receptor-blocking drug 4-DAMP mustard. The fourth cell line used was SH-SY5Y cells stably transfected to express the human 5-hydroxytryptamine-2A (5-HT 2A ) receptor, denoted 5-HT 2A -SH-SY5Y cells (see transfection protocol below). The human 5-HT 2A plasmid cDNA in the pIRES (Neo r ) mammalian expression vector was kindly provided by Dr. Bryan Roth (Department of Biochemistry, Case Western Reserve University, Cleveland, OH). Human neuroblastoma SH-SY5Y cells were transfected with this vector using DOTAP liposomal transfection reagent (Roche, Mannheim, Germany) according to the manufacturer's instructions. Since the plasmid encodes for G-418 resistance, the cells were subjected to G-418 (400 g/ml; Invitrogen, Carlsbad, CA) treatment after 48 h, and the surviving colony was harvested and implemented in this study. Transfected cells were not cloned, but the transfection mix was used. (Roth et al., 1987) and 50.11 nM (Boess and Martin, 1994) . The 5-HT 2A -SH-SY5Y cells were used to determine the effect of benextramine pretreatment on 5-HT 2A receptors by determining agonist-stimulated, G q -mediated activation of phospholipase C (PLC), by measuring [ 3 H]IP x accumulation. These cells were also used for radioligand binding studies to investigate the effect of benextramine on 5-HT 2A -receptor numbers.
The ␣ 2A -L and ␣ 2A -H cells were maintained in a humidified environment and grown to 95% confluency in 150-cm 2 cell culture flasks with Ham's F-12 medium containing 10% fetal bovine serum, 100 units/ml penicillin, and 100 g/ml streptomycin at 37°C in 5% CO 2 . The SH-SY5Y cells were similarly maintained, but the growth medium used was a 1:1 ratio mixture of Ham's F-12 and Dulbecco's modified Eagle's medium (DMEM; Highveld Biological, Gauteng, South Africa) containing 10% bovine serum albumin. The 5-HT 2A -SH-SY5Y cells were maintained as the SH-SY5Y cells but with 400 g/ml G-418.
Preparation and Pretreatment with Irreversible Competitive Antagonists. Cells were seeded in 24-well plates in preparation for the [ 3 H]cAMP, [ 3 H]IP x , or ligand binding assays as described below and maintained for at least 18 h. The ␣ 2A -H and ␣ 2A -L cells were seeded at a density of approximately 3 ϫ 10 5 cells/ml, whereas SH-SY5Y and 5-HT 2A -SH-SY5Y cells were seeded at a density of 6 ϫ 10 5 cells/ml. When cell pretreatments were intended for membrane preparation, the pretreatments were performed directly in the 150-cm 2 culture flasks. Cells attached adequately to the well bottoms, allowing several aspirations and new additions of medium without significant cell loss (confirmed by microscopic observation).
When the experiments were performed, the pretreatments were initiated by incubating the cells with an appropriate concentration (0 M or a concentration Ͼ1000 ϫ K D value) of the reversible antagonist (allowing equilibrium of ligand-receptor binding), whereafter the cells were exposed to different concentrations of the appropriate irreversible antagonist plus the reversible antagonist. This was followed by several rinsing and incubation steps (washing procedure) with phosphate-buffered saline [PBS; containing (w/v) 0.8% NaCl, 0.02% KCl, 0.09% Na 2 HPO 4 , and 0.02% KH 2 PO 4 ] and DMEM to remove all unbound and reversibly bound drugs. The following pretreatment steps were used.
Step 1. ␣ 2A -L or ␣ 2A -H cells were incubated with either 0 or 10 M of the reversible competitive ␣ 2 -adrenoceptor antagonist (Becker et al., 1999) yohimbine hydrochloride (Sigma-Aldrich) in DMEM for 30 min at 37°C in 5% CO 2 , to allow equilibrium of ligand-receptor binding. Likewise, SH-SY5Y cells were incubated with either 0 or 10 M of the reversible competitive nonselective mACh receptor antagonist (Zwart and Vijverberg, 1997) atropine sulfate (Sigma-Aldrich; reported average K i ϭ 0.50 nM for M 3 -mACh receptors by Hirose et al., 2001) in DMEM for 30 min at 37°C in 5% CO 2 to allow equilibrium of receptor binding. 5-HT 2A -SH-SY5Y cells were incubated with either 0 or 10 M of the reversible competitive 5-HT 2 -receptor antagonist ritanserin (Sigma-Aldrich; reported average K i ϭ 0.25 nM for 5-HT 2A receptors by Bonhaus et al., 1997) in DMEM for 30 min at 37°C and 5% CO 2 .
Step 2. Thereafter, ␣ 2A -L or ␣ 2A -H cells were correspondingly incubated with either 0 or 10 M yohimbine plus the indicated concentration of freshly prepared phenoxybenzamine hydrochloride (Sigma-Aldrich) or benextramine tetrahydrochloride (Sigma-Aldrich) (0, 1, 10, or 100 M) for 20 min at 37°C in 5% CO 2 . SH-SY5Y cells were correspondingly incubated with either 0 or 10 M atropine plus the indicated concentration of 4-DAMP mustard (SigmaAldrich) (0, 10, or 100 nM) for 20 min at 37°C in 5% CO 2 . Since 4-DAMP mustard is completely converted to its corresponding active aziridinium ion only after about 30 min in aqueous solution (Thomas et al., 1992) , it was kept for at least 30 min at 37°C in DMEM before use in the assay. 5-HT 2A -SH-SY5Y cells were correspondingly incubated with either 0 or 10 M ritanserin plus the indicated concentration of freshly prepared benextramine (0, 10, or 100 nM) for 20 min at 37°C in 5% CO 2 .
Step 3. Cells were then rinsed twice with PBS and incubated twice with DMEM for 20 min at 37°C in 5% CO 2 to allow dissociation of any reversibly bound drugs, whereafter the cells were used for the functional or ligand binding assays as described below. (Wong, 1994; Wade et al., 1999) . Briefly, cells were radiolabeled by adding 1 Ci per well [2-
3 H]adenine (19 -23 Ci/mmol; Amersham Biosciences UK, Ltd., Little Chalfont, Buckinghamshire, UK), plus 100 ng/ml pertussis toxin (PTX; Sigma-Aldrich) when indicated, at least 18 h before the assay. After the washing procedure (as described above), the assay was initiated by adding DMEM with 1 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma-Aldrich) and 30 M forskolin (Sigma-Aldrich) and the appropriate concentration of the full ␣ 2A -adrenoceptor (Brink et al., 2000) agonist 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine (UK 14,304; Sigma-Aldrich) to construct appropriate semilogarithmic dose-response curves. After a 20-min incubation time at 37°C in 5% CO 2 , the medium was aspirated and the reaction terminated with 1ml of ice-cold 5% (w/v) trichloroacetic acid (TCA; Sigma-Aldrich) containing 1 mM ATP (Sigma-Aldrich) and 1 mM cAMP (Sigma-Aldrich) and allowed to stand for 30 min at 4°C to lyse the cells. The acid soluble nucleotides were separated on Dowex and Alumina columns as described before (Salomon et al., 1974) (Godfrey, 1992; Casarosa et al., 2001 ) but with minor modifications. Briefly, cells were labeled by adding 1 Ci per well myo-[2-3 H]inositol (17 Ci/mmol; Amersham Biosciences UK, Ltd.) in inositolfree medium (minimum essential medium, Earle's base ϩ bovine serum albumin) at least 18 h before the assay. After the pretreatment and washing procedure (as described above), the [ 3 H]IP x assay was initiated by adding a mixture of DMEM, 20 mM LiCl (SigmaAldrich), 25 mM N- [2-hydroxyethyl] piperazine-NЈ-[2-ethanesulphonic acid] (HEPES) (Sigma-Aldrich), and the appropriate concentration of the full mACh receptor agonist (Olianas and Onali, 1991) methacholine chloride (Sigma-Aldrich) or the endogenous 5HT 2A receptor agonist serotonin creatinine sulfate (Sigma-Aldrich) to construct appropriate semilogarithmic dose-response curves. After a 60-min incubation at 37°C and 5% CO 2 , the medium was aspirated, and the reaction was terminated with 1 ml of ice-cold 10 mM formic acid (Saarchem-Holpro Analytic, Krugersdorp, Gauteng, South Africa) and was let to stand for at least 90 min at 4°C to lyse the cells. The To determine relative receptor numbers in ␣ 2A -H, SH-SY5Y, and 5HT 2A -SH-SY5Y cells after drug pretreatments as described above, we performed single-dose saturation binding assays. Cells were plated and incubated for at least 18 h at 37°C in 5% CO 2 as before but without a radioligand. The cells were then rinsed once with reduced serum minimum essential medium (UltraMEM), whereafter the assay was initiated by adding UltraMEM with 0 or 10 M reversible jpet.aspetjournals.org competitive antagonist (to define nonspecific binding) plus the appropriate concentration of radioligand. After a 30-min incubation at 37°C in 5% CO 2 , the medium was aspirated and the cells rinsed twice with ice-cold PBS, and the reaction was terminated with 1-ml icecold 5% (w/v) TCA and was let to stand for at least 30 min at 4°C to lyse the cells. The TCA from each well was then transferred directly into scintillation vials, and the radioactivity was counted. The relative ␣ 2A -adrenoceptor concentrations in ␣ 2A -H cells (after the various pretreatments with the appropriate irreversible competitive antagonists and washing procedure as described above) were determined from specific binding of 5 nM [O-methyl-3 To determine the pK i value of the ␣ 2A -adrenoceptor agonist UK 14,304 at ␣ 2A -adrenoceptors in ␣ 2A -H cells after pretreatment with 10 M yohimbine and 100 M phenoxybenzamine or 100 M benextramine as described above, we performed competition binding assays in whole ␣ 2A -H cells against 5 nM [O-methyl-3 H]yohimbine. In preparation for the competition binding experiments, the cells were plated and incubated as before but without a radioligand. Cells were then rinsed once with UltraMEM, whereafter the assay was initiated by adding UltraMEM with 5 nM [O-methyl-3 H]yohimbine and different concentrations of UK 14,304. After a 30-min incubation at 37°C in 5% CO 2 , the medium was aspirated, the washing procedure as described above was followed, and the reaction was terminated with 1 ml of 5% (w/v) TCA and let to stand for at least 30 min to allow the cells to lyse. The TCA from each well was then transferred directly into scintillation vials, and the radioactivity (bound [O-methyl-3 H]yohimbine) was counted. Preparing Membranes from ␣ 2A -H Cells. After the appropriate pretreatment of whole ␣ 2A -H cells (see above), the cells were washed twice with PBS, the cell monolayer was loosened with ethylenediaminetetraacetic acid (EDTA) in PBS (0.02% w/v), and the cells were scraped from the culture flask surface with a cell scraper. The cell suspension was centrifuged in a bench top centrifuge (5411g, 4°C, 15 min), the supernatant was discarded, and the pellet was washed twice with ice-cold PBS, whereafter the pellet was resuspended in 1 mM Tris buffer (pH 7.4). The cell suspension was tumbled for 15 min at 4°C, homogenized with a Teflon homogenizer, and centrifuged at 1000g in a Beckman ultracentrifuge at 4°C for 15 min. The supernatant was collected and kept on ice while the pellet was resuspended in the Tris buffer and the preceding procedure repeated to collect all protein. The resulting supernatants were centrifuged at 40,000g in a Beckman ultracentrifuge at 4°C for 60 min. The resulting pellet was resuspended and homogenized in TME buffer (50 mM Tris, 10 mM MgCl 2 , and 1 mM EDTA, pH 7.4). Protein concentrations were determined with the Bradford method (Bradford, 1976), using bovine serum albumin as a standard and determining absorbance with a 96-well plate reader and a 560-nm filter (Labsystems Multiskan RC; Thermo Electron Corporation, Waltham, MA). Snap-frozen aliquots were stored at Ϫ86°C for up to 4 weeks.
Measuring [ 35 S]GTP␥S Binding in
35 S]GTP␥S binding assay to ␣ 2A -H membranes was based on the procedures previously described (Sternweis and Robishaw, 1984; Yang and Lanier, 1999) but adapted for the present study. Immediately before the [ 35 S]GTP␥S binding assays, the membranes were thawed on ice, and the protein concentrations were adjusted to 1.4 g/l by adding the appropriate volume of TME dilution buffer. Freshly prepared assay buffer (0.5 nM [
35 S]GTP␥S, 1 M GDP, 50 mM Tris, 5 mM MgCl 2 , 1 mM EDTA, 100 mM NaCl, and 1 mM dithiothreitol (DTT), pH 7.4, at 4°C) was used to prepare a concentration range of UK 14,304. In each test tube, 90 l of the assay buffer containing the appropriate concentration of UK 14,304 was added and heated for 5 min at 25°C in a water bath. Thereafter, 10-l membrane was added and incubated for 40 min at 25°C in the water bath. After the incubation, 3 ml of ice-cold TMN washing buffer (20 mM Tris, 25 mM MgCl 2 , and 100 mM NaCl, pH 7.4) was added to each membrane sample, and it was immediately filtered through Whatman GF/C filters (Kent, UK), using a Hoefer filtration rig under vacuum. Each sample was washed three times with icecold TMN buffer. (Sternweis and Robishaw, 1984; Graber et al., 1992) but adapted to accommodate the pretreatment with benextramine. The G␣ o protein was diluted to a concentration of 8 ng/l with a sample dilution buffer (10 mM HEPES, 1 mM EDTA, 1 mM DTT, and 0.1% w/v nonaethylene glycol monododecyl ether, pH 8.0) and kept on ice. Before measuring the binding of [
35 S]GTP␥S to G␣ o , the protein was pretreated with either 0 M or 100 M benextramine for 2 h at 4°C or for 30 min at 25°C. Immediately after pretreatment, the benextramine pretreatment groups were divided into 10-l samples in test tubes, and 10 l of dilution buffer was added on ice. Thereafter, a 20-l binding cocktail (0.8 nM [
35 S]GTP␥S, 2 M GTP␥S in 50 mM HEPES, 1 mM EDTA, 40 mM MgCl 2 , 200 mM NaCl, and 1 mM DTT, pH 8.0) was added to each test tube at the indicated temperature (4°C or 25°C). After incubation, 3 ml of ice-cold TMN washing buffer (pH 8.0) was added to each sample, and the bound [ 35 S]GTP␥S separated from the free fraction by rapid filtration through type HAWP nitrocellulose membrane filters (Millipore, Billerica, MA), placed on a Hoefer filtration rig under vacuum. Each sample was washed three times with ice-cold TMN buffer. Nonspecific binding of [ 35 S]GTP␥S was defined by samples with assay buffer but no G␣ o protein. Filters were air-dried, whereafter radioactivity was determined by liquid scintillation counting.
Data Analysis. Data from all studies were obtained from triplicate observations from at least three separate, comparable experiments, and results are expressed as S.E.M. Semilogarithmic doseresponse curves were constructed as least-square nonlinear fits, utilizing the computer software GraphPad Prism (version 3.03 for Microsoft Windows; GraphPad Software, San Diego, CA). Where data of dose-response curves are expressed as a percentage of control without drug, no statistical significant differences were found in the control values of second messenger accumulation among the different pretreatments with each irreversible antagonist. One-site competition binding curves were constructed as least-square nonlinear fits, and the K i values were calculated from the IC 50 value, applying the K D value of the radioligand into the built-in Cheng-Prusoff correction of the software. Student's two-tailed, unpaired t test was implemented to compare the E max , pEC 50 , and pK i values. All reported p values are after the Bonferroni correction for multiple comparisons (when appropriate), and a value of p Ͻ 0.05 was taken as statistically significant. [O-methyl-3 H]yohimbine could be noted in bar b 1 (84 Ϯ 1.5%) as compared with bar a 1 (100 Ϯ 1.1%), which may represent some residual cold (nonradioactive) yohimbine after the washing steps and of which the negligible effect on receptor-mediated functional response is illustrated further below (Fig. 2) .
Results

Specific
Likewise, Fig should be noted in bar d 1 (87 Ϯ 3.4%) as compared with bar c 1 (100 Ϯ 1.5%), which may represent some residual cold (nonradioactive) yohimbine after the washing steps and of which the negligible effect on receptor-mediated functional response is illustrated further below (Fig. 2) . The reductions in the specific binding of [O-methyl-3 H]yohimbine observed in bars d 3 (73 Ϯ 2.9%) and d 4 (71 Ϯ 2.8%) compared with bar d 1 (87 Ϯ 3.4%) may be due to incomplete receptor protection by 10 M yohimbine but are practically insignificantly small in terms of its expected effect on receptor-mediated response (illustrated further below, Fig. 2 ). From the bars in Fig. 1, B and D (when compared with the corresponding bars in Fig. 1 , A and C), it follows that 10 M yohimbine prevented the irreversible antagonist from reducing receptor binding at ␣ 2A -adrenoceptors.
Similarly, Fig. 1 , E and F depicts the specific binding of [N-methyl-3 H]4-DAMP to mACh receptors in SH-SY5Y cells before and after pretreatment with different concentrations of 4-DAMP mustard for 20 min, either without protection of the mACh receptors (0 M atropine) or with protection of the mACh receptors (10 M atropine). It can be seen in Fig. 1E that 4-DAMP mustard decreased specific binding (p Ͻ 0.01 for comparison of bars e 1 and e 2 or of bars e 1 and e 3 ) in the absence of receptor protection. The difference in specific binding between 10 and 100 nM 4-DAMP mustard was not statistically significant (p ϭ 0.11 for comparison of bars e 2 and e 3 ). As with phenoxybenzamine and benextramine, a small reduction in the specific binding of the radioligand should be noted in bar f 1 (84 Ϯ 2.5%) as compared with bar e 1 (100 Ϯ 3.1%), which may represent some residual cold (nonradioactive) atropine after the washing steps and of which the negligible effect on receptor-mediated functional response is (Fig. 2) . From the bars in Fig. 1F (when compared with the corresponding bars in Fig. 1E ), it can be seen that increasing concentrations of 4-DAMP mustard with receptor protection by atropine did not cause a similar prominent decrease in receptor number (p Ͼ 0.05 for comparison of bars f 1 and f 2 , bars f 1 and f 3 , and bars f 2 and f 3 ), and it follows that 10 M atropine prevented the irreversible antagonist from reducing receptor binding at mACh receptors.
Specific Binding and Second Messenger Formation before and after Pretreatment with the Reversible Antagonists. Figure 2A depicts the specific binding of [O-methyl-3 H]yohimbine to ␣ 2A -adrenoceptors in ␣ 2A -H cells after pretreatment with 0 or 10 M yohimbine, but no irreversible antagonist. Although there was a difference in specific binding of [O-methyl-3 H]yohimbine of about 13.4% (p ϭ 0.01) between the 0 or 10 M yohimbine pretreatment groups, this difference appears to be functionally insignificant (i.e., negligible effect on receptor-mediated functional response) as shown by the corresponding functional data in Fig. 2B , depicting the dose-response curves of the ␣ 2A -adrenoceptor full agonist UK 14,304 in ␣ 2A -H cells after the pretreatments with 0 or 10 M yohimbine. These dose-response curves were practically superimposed with no statistically significant difference between the pEC 50 values (p ϭ 0.78) or E max values (p ϭ 0.37). This is predicted also by theory, where a reduction in receptor concentration of 13.4% in a system with significant spare receptors, should not significantly alter the EC 50 value of a dose-response curve.
Likewise, Fig. 2C depicts the specific binding of [N-methyl-3 H]4-DAMP to mACh receptors in SH-SY5Y cells after pretreatment with 0 or 10 M atropine, but no irreversible competitive antagonist. Although there was a difference in specific binding of [N-methyl-3 H]4-DAMP of about 16% (p ϭ 0.02) between the 0 or 10 M atropine pretreatment groups, this difference appears to be functionally insignificant (i.e., negligible effect on receptor-mediated functional response) as shown by the corresponding functional data in Fig. 2D , depicting the dose-response curves of the mACh receptor full agonist methacholine in SH-SY5Y cells after pretreatments with 0 or 10 M atropine. The dose-response curves were practically superimposed with no statistically significant difference between the pEC 50 values (p ϭ 0.50) or E max values (p ϭ 0.76). Again, this is in line with theoretical predictions, as mentioned above.
A similar approach was intended for 5-HT 2A receptors, by measuring the specific binding of [ 3 H]ketanserin to 5-HT 2A receptors in 5-HT 2A -SH-SY5Y cells after pretreatment with 0 or 10 M ritanserin but no irreversible competitive antagonist. However, results from radioligand binding studies showed that, under the experimental conditions used, 5-HT 2A receptors could not be significantly protected against benextramine with ritanserin. Therefore, none of the doseresponse curves in this cell line, as presented further below in this manuscript, were constructed in the presence of ritanserin and there was no need to include such curves in Fig. 2 .
Agonist-Mediated Responses before and after Pretreatment with the Irreversible Antagonists with or without Receptor Protection. Figure 3A depicts doseresponse curves of the ␣ 2A -adrenoceptor full agonist UK 14,304 in ␣ 2A -L cells after pretreatment with different concentrations of phenoxybenzamine for 20 min. As the concentration of phenoxybenzamine was increased, the dose-response curves of UK 14,304 shifted to the right (1 and 10 M), and at the highest concentration (100 M), the E max value was also suppressed (E max a 4 /a 1 ratio ϭ 0.37, p Ͻ 0.05). Similarly, Fig. 3C depicts dose-response curves of UK 14,304 in ␣ 2A -L cells after pretreatment with different concentrations of benextramine for 20 min. As the concentration of the benextramine was increased, the dose-response curves of UK 14,304 initially shifted to the right (1 M benextramine: EC 50 shift c 2 /c 1 ratio ϭ 23, p Ͻ 0.05), and at higher concentrations (10 and 100 M), the E max value was suppressed (E max c 3 /c 1 ratio ϭ 0.56, p Ͻ 0.05; E max c 4 /c 1 ratio ϭ 0.29, p Ͻ 0.05). However, when the ␣ 2A -adrenoceptors were protected from binding to the irreversible competitive antagonist, the antagonism by the irreversible competitive antagonists were not abolished, as illustrated in Fig. 3 Figure 3E depicts dose-response curves of the mACh receptor full agonist methacholine in SH-SY5Y cells after pretreatment with different concentrations of 4-DAMP mustard for 20 min. The E max value was statistically significantly suppressed at 100 nM 4-DAMP mustard for 20 min (E max e 3 /e 1 ratio ϭ 0.75, p Ͻ 0.05) but not at 10 nM (E max e 2 /e 1 ratio ϭ 0.89, p Ͼ 0.05). When the mACh receptors were protected from binding to the irreversible competitive antagonist, as presented in Fig. 3F , the dose-response curves were practically superimposed with no apparent changes in the antagonism.
Affinity of UK 14,304 for ␣ 2A -Adrenoceptors before and after Pretreatment with Phenoxybenzamine or Benextramine. Since Fig. 3 indicated that irreversible antagonism by benextramine or phenoxybenzamine was not abolished by ␣ 2A -adrenoceptor protection, it was investigated whether or not the irreversible noncompetitive antagonism by phenoxybenzamine or benextramine (i.e., observed rightward shift of dose-response curves of UK 14,304 after receptor protection) was due to an altered affinity of the ␣ 2A -adrenoceptor for the full agonist UK 14,304. The pK i value of UK 14,304 was determined from competition binding curves against 5 nM [O-methyl-3 H]yohimbine in ␣ 2A -H cells before and after pretreatment with 100 M phenoxybenzamine (Fig. 4A) or benextramine (Fig. 4B) for 20 min, with ␣ 2A -adrenoceptor protection by 10 M yohimbine. Irreversible antagonist pretreatment did not alter the ␣ 2A -adrenoceptor receptor affinity for UK 14,304 and apparently not the binding profile as well, since the competition binding curves before and after the irreversible antagonist were practically superimposed. The pK i values were determined as pK i ϭ 6.64 Ϯ 0.05 versus pK i ϭ 6.77 Ϯ 0.06 after 0 or 100 M phenoxybenzamine, respectively (p ϭ 0.16), and pK i ϭ 6.91 Ϯ 0.20 versus pK i ϭ 6.82 Ϯ 0.13 after 0 or 100 M benextramine, respectively (p ϭ 0.73).
[ 35 S]GTP␥S Binding to G␣ i Proteins in ␣ 2A -H Membranes after Benextramine Pretreatment, with or without ␣ 2A -Adrenoceptor Protection. Since competition binding studies with UK 14,304 above revealed that benextramine does not affect agonist affinity, it follows that the noncompetitive irreversible antagonism should involve the inhibition of the ␣ 2A -adrenoceptor signal-transduction. We therefore conducted G i protein-[ 35 S]GTP␥S binding studies to investigate whether the noncompetitive antagonism by benextramine is due to irreversible binding to a site at the receptor and/or G protein level, or whether the binding is located downstream to the G protein in the signal transduction system. As before, ␣ 2A -H cells were pretreated with 0 or 100 M benextramine for 20 min at 37°C, plus 0 M yohimbine, or 10 M yohimbine to protect the ␣ 2A -adrenoceptors from binding to benextramine. After washing procedures to remove all unbound and reversibly bound drugs (as described above), membranes were prepared. Figure 5 depicts doseresponse curves of the full ␣ 2A -adrenoceptor agonist UK 35 S]GTP␥S binding to G proteins in these membranes. In Fig. 5A , a concentration-dependent response of UK 14,304 was observed in membranes pretreated with drug-free medium (i.e., control curve a 1 , pretreated with 0 M yohimbine plus 0 M benextramine). As expected, when the membranes were pretreated with benextramine (i.e., curve a 2 , pretreated with 0 M yohimbine plus 100 M benextramine), the response to UK 14,304 was totally abolished (from E max , p Ͻ 0.01). When the membranes were pretreated with yohimbine alone (Fig. 5B, curve b 1 , pretreated with 10 M yohimbine plus 0 M benextramine), a dose-response curve was obtained similar to curve a 1 , confirming previous results that residual yohimbine after the washing procedure did not affect receptor function, as evidenced by Fig. 2 . Importantly, however, when the ␣ 2A -adrenoceptors were protected from binding to benextramine during the pretreatment (Fig. 5B, curve b 2 , pretreated with 10 M yohimbine plus 100 M benextramine), the dose-response curve of UK 14,304 was completely suppressed as was found without receptor protection, as represented in curve a 2 (from E max , p Ͻ 0.01). Results suggest that the protection of ␣ 2A -adrenoceptors with yohimbine does not prevent benextramine from inhibiting the binding of [
35 S]GTP␥S to the membranes and, therefore, G i -mediated signaling through the receptor.
Binding of [ 35 S]GTP␥S to G␣ o before and after Incubation with Benextramine at Different Incubation
Times and Temperatures. G␣ o is a relatively stable GTP binding protein of the G i/o family and has been shown to constitutively (in the absence of receptor and agonist) bind guanine nucleotides (Sternweis and Robishaw, 1984) . To investigate whether benextramine directly binds to the G protein nucleotide binding site to inhibit GTP binding, G␣ o was pretreated with 0 or 100 M benextramine for 120 min at 4°C, or for 30 min at 25°C, whereafter the [ 35 S]GTP␥S binding was measured, as presented in Fig. 6 . After pretreatment with 0 or 100 M benextramine for 120 min at 4°C, the specific binding obtained is depicted in Fig. 6A . As can be seen from Fig. 6A , benextramine has not significantly reduced the binding of [
35 S]GTP␥S to G␣ o (p ϭ 0.80), and the amount of [
35 S]GTP␥S bound after pretreatment with 0 or 100 M benextramine was measured as 17.2 Ϯ 3.0 and 16 Ϯ 3.1 fmol/ng membrane protein, respectively. Likewise, after pretreatment with 0 or 100 M benextramine for 30 min at 25°C, the specific binding obtained is depicted in Fig. 6B . As can be seen from Fig. 6B Sternweis and Robishaw (1984) , purified G proteins (such as G␣ o ), could be stored at Ϫ80°C or even on ice (4°C) for several weeks with little or no loss of binding activity. Thus the observed overall significant reduction in binding of [
35 S]GTP␥S to G␣ o after pretreatment with benextramine for 30 min at 25°C may be due to reduced biological activity of the G␣ o protein, since it is well known that higher temperatures cause conformational changes that may modulate or destroy its biological activity. G s -Mediated [ 3 H]cAMP Accumulation in ␣ 2A -H Cells after Pretreatment with Benextramine, with or without ␣ 2A -Adrenoceptor Protection. Since our previous observations investigated the noncompetitive antagonism by benextramine at ␣ 2A -adrenoceptors via a G i -mediated response only, it was important to investigate whether similar noncompetitive antagonism by benextramine can be observed via a G s protein-mediated response but with the same receptors and effector (adenylyl cyclase). It has been shown before that after PTX treatment of ␣ 2A -H cells, the ␣ 2A -adrenoceptors couple to G s proteins to stimulate adenylyl cyclase activity (Brink et al., 2000) . Figure 7 displays doseresponse curves of UK 14,304 in PTX-treated whole ␣ 2A -H cells after pretreatment with 0 or 100 M benextramine plus 0 M (Fig. 7A) or 10 M yohimbine (Fig. 7B) for 20 min at 37°C. Without protection of the ␣ 2A -adrenoceptors (Fig. 7A) , 100 M benextramine abolished the agonist-induced response (E max for a 1 ϭ 100 Ϯ 13.1% and E max for a 2 ϭ Ϫ3.6 Ϯ 7.5%, p Ͻ 0.01). When the ␣ 2A -adrenoceptors were protected by 10 M yohimbine, the G s -mediated response was only In SH-SY5Y cells, benextramine partially suppressed the methacholine-mediated response (E max values were 100 Ϯ 17.2% for curve a 1 and 25.2 Ϯ 8.6% for curve a 2 , p Ͻ 0.05). (Fig. 8) , it was important to determine whether this inhibition could be ascribed to a reduction in receptor number, or whether noncompetitive antagonism is displayed by benextramine.
After pretreatment of SH-SY5Y whole cells with 0 M or 100 M benextramine for 20 min at 37°C, plus 0 M or 10 M atropine (Ͼ1000 ϫ K i value, to protect mACh receptors from binding to benextramine), radioligand binding assays were conducted to determine the relative number of receptors. Figure 9 , A and B depict the specific binding of [ 3 H]4-DAMP to mACh receptors in SH-SY5Y cells after pretreatment with 0 M or 100 M benextramine. In the absence of receptor protection by atropine (Fig. 9A) , benextramine pretreatment However, after pretreatment with 10 M atropine to protect the mACh receptors from benextramine (Fig. 9B) , the specific binding was also significantly decreased from 76.8 Ϯ 3.2% (bar b 1 ) to 42.3 Ϯ 2.2% (bar b 2 ) (p Ͻ 0.001).
Likewise, after pretreatment of 5-HT 2A -SH-SY5Y whole cells with 0 M or 100 M benextramine for 20 min at 37°C, plus 0 M or 10 M ritanserin (Ͼ1000 ϫ K i value, to protect 5-HT 2A receptors from binding to benextramine), radioligand binding assays were conducted to determine the relative number of receptors. 
Discussion
The Experimental Conditions and Pretreatments Are Suitable for the Evaluation of Noncompetitive Mechanisms by the Irreversible Competitive Antagonists. As expected, phenoxybenzamine (Fig. 1A) and benextramine (Fig. 1C) pretreatments decrease the ␣ 2A -adrenoceptor number in ␣ 2A -H cells and that 4-DAMP mustard (Fig.  1E) decreased the mACh receptor number in SH-SY5Y cells. The binding of phenoxybenzamine (Fig. 1B) and benextramine (Fig. 1D) to ␣ 2A -adrenoceptors were effectively prevented by yohimbine, whereas atropine effectively prevented the binding of 4-DAMP mustard to mACh receptors (Fig. 1F) . Therefore, the irreversible antagonists were used at sufficient concentrations and incubation times to eliminate a significant fraction of the operational receptors and the concentrations of the reversible antagonists used were sufficient antagonism at ␣ 2A -adrenoceptors also when measuring G smediated responses (Fig. 7) .
Taken together, it can be postulated that benextramine most likely exhibits allotopic interactions at the ␣ 2A -adrenoceptor macromolecule or binds to a common GPCR coupling site on the G i and G s proteins. The noncompetitive antagonism by benextramine at ␣ 2A -adrenoceptors is substantially less with G s -than with G i -mediated responses, suggesting that this action is dependent on the G protein type involved in the GPCR signaling. This complies with data suggesting distinct basic residues of the ␣ 2A -AR that mediate G i and G s activation, respectively (Wade et al., 1999) . Also, whereas classical irreversible antagonists such as the haloalkylamines are believed to form uncomplicated covalent bonds with the receptor, it has been proposed that benextramine inactivates receptors at distinct sites via a disulfide-thiol interchange reaction (Melchiorre et al., 1979; Brasili et al., 1980 Brasili et al., , 1986 Melchiorre, 1981; Melchiorre and Gallucci, 1983; Giardinà et al., 1996) , thereby affecting the stereochemical properties of cysteine amino acid residues and probably disrupting the coupling of the ␣ 2A -AR to G i more than to G s .
Benextramine Irreversibly Inhibits Signaling of Both Muscarinic Acetylcholine (mACh) Receptors and 5-HT 2A Receptors via G q . Both mACh receptors (Sorensen et al., 1999) and 5-HT 2A receptors (Berridge, 1993) have been shown to signal through PTX-insensitive G q proteins to activate PLC. We have also confirmed that the agonist-induced, mACh receptor-mediated PLC activation in SH-SY5Y cells is abolished by the PLC inhibitor U-73122 (Bleasdale and Fisher, 1993) and also that this mACh receptor-response is PTX-insensitive (data not shown). Data from the present study show that benextramine irreversibly inhibits the methacholine-induced G q -mediated signaling of mACh receptors in SH-SY5Y cells (Fig. 8A ) but that these receptors could not be protected by 10 M atropine (i.e., Ͼ1000 ϫ K D value) (Fig. 9B) . These results suggest that benextramine exhibits allotopic interactions at mACh receptors. In contrast, the antagonism by benextramine at mACh receptors in isolated guinea pig atrium and ileum was reversible when measuring smooth muscle contraction . Species and tissue differences may explain this apparent contradiction.
Benextramine also irreversibly inhibits the serotonin-induced, G q -mediated signaling of 5-HT 2A receptors (Fig. 8B) , which cannot be prevented by ritanserin at a relatively high concentration of 10 M (Ͼ1000 ϫ K D value) (Fig. 9D) . These results suggest that benextramine exhibits allotopic interactions, displaying irreversible noncompetitive antagonism at 5-HT 2A receptors. Antagonism by benextramine at 5-HT 1A receptors has been shown before (Stanton and Beer, 1997) , and it therefore does not seem to act selectively at a particular 5-HT receptor subtype.
These data suggest that benextramine binds to sites distinct from the primary binding sites (i.e., nonoverlapping) at mACh and 5-HT 2A receptors. These allotopic interactions may cause sterical changes in the receptor macromolecule, hindering binding of the ligand to the primary binding site of the receptor.
Final Conclusions and Implications of This Study. We provide here evidence of irreversible noncompetitive antagonism by phenoxybenzamine and benextramine at ␣ 2A -adrenoceptors in addition to their known irreversible specific antagonism. Agonist affinity is not influenced, but signal transduction may be modulated via allotopic interactions. Irreversible noncompetitive antagonism by benextramine at ␣ 2A -adrenoceptors is G protein-dependent. Benextramine inhibits agonist-induced responses at three different GPCR types, involving signaling via three of the four main families of G proteins (i.e., G i/o , G s , and G q/11 families) in different pharmacological systems, presumably by binding to distinct binding sites at the various receptor types.
Under the conditions specified, 4-DAMP mustard does not display irreversible noncompetitive antagonism at mACh receptors, whereas benextramine exhibits allotopic interactions at mACh receptors and 5-HT 2A receptors, preventing ligand binding to the agonist binding site. However, the current data does not exclude the possibility that receptor-G protein coupling is also inhibited at mACh receptors and 5-HT 2A receptors, as was suggested for ␣ 2A -adrenoceptors. Further investigation is needed to clarify the exact mechanisms of action of benextramine.
Benextramine may prove to be a useful experimental tool in investigating the signaling mechanisms of G protein-coupled receptors. Also, the mere confirmation of syntopic interactions (e.g., by receptor-radioligand binding studies) does not rule out irreversible noncompetitive antagonism. Irreversible competitive antagonists should be utilized with due care for the implementation of any procedure where irreversible competitive antagonism is desired or intended (e.g., the Furchgott analysis). In such cases, pure irreversible competitive antagonism should be verified under the experimental conditions applied. Finally, we propose that irreversible noncompetitive mechanisms of antagonism could potentially contribute to the therapeutic response of phenoxybenzamine in the treatment of pheochromocytoma, but the specificity, scope, or clinical significance of this mechanism needs further investigation.
